Latest News & Press Releases

October 20, 2022

Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology

SAN DIEGO, CA, October 20, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Paul A. Smith, Ph.D., as senior vice president of biology. “Paul has extensive drug discovery experience, including in transitioning therapies from research to clinical development, as […]

Read More »

September 29, 2022

Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer

SAN DIEGO, CA, September 29, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Matthew Caldemeyer as chief business officer. “We are excited to welcome Matt to our executive leadership team,” said Nancy Whiting, Pharm.D., chief executive officer of Recludix. […]

Read More »

September 13, 2022

Recludix Pharma Announces the Appointment of Seasoned Biotech Leader Athena Countouriotis, M.D., as the Chairperson of the Board of Directors

SAN DIEGO, CA, September 13, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Athena Countouriotis, M.D., as the chairperson of the board of directors. “Athena is both a distinguished biotech business leader as well as a physician and oncologist, […]

Read More »

January 6, 2022

Recludix Pharma Announces Scientific Advisory Board

SAN DIEGO, CA, January 6, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the establishment of its scientific advisory board. “We are thrilled to have established a group of distinguished scientific thought leaders as advisors to the company,” said Nancy Whiting, Pharm.D., […]

Read More »

November 15, 2021

Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO

–Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underway –Nancy Whiting, Pharm.D., an industry veteran and one of Fierce Pharma’s Fiercest Women in Life Sciences in 2020, named as chief executive officer –Pedigreed senior leadership team and Series A investors disclosed SAN DIEGO, CA, November 15, 2021 – Recludix […]

Read More »